tirzepatide elimination half life Mean (one-sided standard deviation) plasma concentration profile of Pharmacokinetics in plasma in humans:
Description
Patients treated with tirzepatide in the SURMOUNT program experienced average weight loss of 20% or more, and many reported improved psychological well-being alongside physical changes
Tirzepatide is a novel medication approved by the FDA for the treatment of type 2 diabetes (marketed as Mounjaro) and chronic weight management (marketed as Zepbound)
Alexis Missick MBChB
Additionally, tirzepatide acts on central appetite regulation pathways in the hypothalamus, promoting satiety and reducing caloric intake, which contributes to its weight loss effects
If a patient presents with some unfamiliar Long Covid symptom, this is confidential information, not to be shared outside a doctors surgery
